Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed diagnosis of adenocarcinoma of the prostate History/physical examination with digital rectal examination of the prostate
- Histological evaluation of prostate biopsy with assignment of Gleason score to the biopsy material.
- Clinical stage T1-3 (AJCC 7th edition).
- Males age ≥ 18
- Patient must be able to provide study-specific informed consent prior to study entry.
- Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
Exclusion Criteria:
- Evidence of distant metastases
- Regional lymph node involvement
- Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer
- Previous pelvic irradiation, prostate brachytherapy
- Previous or concurrent cytotoxic chemotherapy for prostate cancer
There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease
No life expectancy restrictions will apply
Performance Status will not be considered
Sites / Locations
- Hoag Memorial Hospital Presbyterian
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
Elekta Versa HD
Agility Systems
This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.